他莫昔芬治疗对乳腺癌幸存者生育力的影响
基于FUCHSIA女性研究的人群队列,纳入397例22-45岁乳腺癌幸存者,分析他莫昔芬使用与确诊后生育及卵巢储备的关系。曾用他莫昔芬者确诊后生育可能性显著降低(校正后HR 0.25;95%CI 0.14, 0.47),但卵巢储备指标未降低,抗苗勒管激素几何均值反而更高(2.47倍;95%CI 1.08, 5.65)。
要点
- 曾用他莫昔芬的乳腺癌幸存者确诊后生育可能性低于从未使用者(校正后HR 0.25;95%CI 0.14, 0.47)。
- 校正混杂因素后,他莫昔芬使用者抗苗勒管激素几何均值是从未使用者的2.47倍(95%CI 1.08, 5.65)。
- 他莫昔芬使用者窦卵泡计数较从未使用者高(风险比1.21;95%CI 0.84, 1.73),未达统计学显著。
核心结论
- 曾用他莫昔芬的乳腺癌幸存者确诊后生育可能性低于从未使用者,但他莫昔芬使用者卵巢储备未低于从未使用者。
研究设计与样本
- 基于FUCHSIA女性研究的人群队列研究,纳入397例22-45岁乳腺癌幸存者,癌症确诊年龄20-35岁且确诊后至少2年,其中108例还参加了门诊访视。
主要发现
- 曾用他莫昔芬者确诊后生育可能性低于从未使用者(HR 0.29;95%CI 0.16, 0.54)。
- 校正确诊年龄、烷化剂暴露和种族后,曾用他莫昔芬者生育HR为0.25(95%CI 0.14, 0.47)。
- 校正潜在混杂因素后,他莫昔芬使用者抗苗勒管激素几何均值是从未使用者的2.47倍(95%CI 1.08, 5.65)。
- 校正相同变量后,他莫昔芬使用者窦卵泡计数高于从未使用者(风险比1.21;95%CI 0.84, 1.73)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether tamoxifen use is associated with decreased ovarian reserve and decreased likelihood of having a child after a breast cancer diagnosis, using data from the Furthering Understanding of Cancer, Health, and Survivorship in Adult (FUCHSIA) Women Study. DESIGN: Population-based cohort study. SETTING: Not applicable. PATIENT(S): Three hundred ninety-seven female breast cancer survivors aged 22-45 years whose cancer was diagnosed between ages 20 and 35 years and who were at least 2 years after diagnosis; 108 survivors also participated in a clinic visit. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Time to first child after cancer diagnosis, clinical measures of ovarian reserve (antimüllerian hormone [AMH] and antral follicle count [AFC]) after cancer. RESULT(S): Women who had ever used tamoxifen were substantially less likely to have a child after the breast cancer diagnosis (hazard ratio [HR] 0.29; 95% confidence interval [CI], 0.16, 0.54) than women who had never used tamoxifen. After adjusting for age at diagnosis, exposure to an alkylating agent, and race, the HR was 0.25 (95% CI, 0.14, 0.47). However, after adjusting for potential confounders, women who had used tamoxifen had an estimated geometric mean AMH level 2.47 times higher (95% CI, 1.08, 5.65) than women who had never taken tamoxifen. Antral follicle count was also higher in the tamoxifen group compared with the tamoxifen nonusers when adjusted for the same variables (risk ratio 1.21; 95% CI, 0.84, 1.73). CONCLUSION(S): Breast cancer survivors who had used tamoxifen were less likely to have a child after breast cancer diagnosis compared with survivors who never used tamoxifen. However, tamoxifen users did not have decreased ovarian reserve compared with the tamoxifen nonusers.
引用
- Shandley LM, Spencer JB, Fothergill A, et al. Impact of tamoxifen therapy on fertility in breast cancer survivors. Fertil Steril. 2016. PMID: 27887709. doi:10.1016/j.fertnstert.2016.10.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。